Biomarkers and cell phenotypes in TB patients with minimal or persisting lung inflammation post-anti-TB treatment and ex-vivo atorvastatin immunomodulatory effects on M. tuberculosis-infected PBMC

Simple item page
dc.contributor.advisorGuler, Reto
dc.contributor.advisorThienemann, Friedrich
dc.contributor.advisorOzturk, Mumin
dc.contributor.authorMotaung, Bongani
dc.date.accessioned2025-03-04T10:38:45Z
dc.date.available2025-03-04T10:38:45Z
dc.date.issued2024
dc.date.updated2025-03-04T10:33:22Z
dc.description.abstractUnresolved lung inflammation post-anti-TB treatment necessitates the evaluation of additional host-directed therapies (HDT). Statins, recognized for their pleiotropic effects, show potential as immunomodulators to reduce post-TB lung inflammation. The ongoing StatinTB clinical trial utilizes a double-blind, randomized, placebo-controlled approach post-anti-TB treatment to assess the safety and efficacy of atorvastatin in reducing post TB lung inflammation. At the end of TB treatment, Mtb culture-negative participants were stratified into minimal (Arm A, Total Lung Glycolysis (TLG) < 50 SUV) or persisting (Arm B/C, TLG ≥ 50 SUV) lung inflammation using Positron Emission Tomography/Computed Tomography (PET/CT) scan. Arm B/C received atorvastatin (40mg/day) or placebo for 12 weeks, and this data remains currently blinded. Study participants were evaluated for hematological, biochemical, and inflammatory parameters where ALP, proBNP, vitamin D, and CRP showed significant increases in Arm B/C compared to Arm A at
dc.identifier.apacitationMotaung, B. (2024). <i>Biomarkers and cell phenotypes in TB patients with minimal or persisting lung inflammation post-anti-TB treatment and ex-vivo atorvastatin immunomodulatory effects on M. tuberculosis-infected PBMC</i>. (). University of Cape Town ,Faculty of Health Sciences ,Department of Pathology. Retrieved from http://hdl.handle.net/11427/41095en_ZA
dc.identifier.chicagocitationMotaung, Bongani. <i>"Biomarkers and cell phenotypes in TB patients with minimal or persisting lung inflammation post-anti-TB treatment and ex-vivo atorvastatin immunomodulatory effects on M. tuberculosis-infected PBMC."</i> ., University of Cape Town ,Faculty of Health Sciences ,Department of Pathology, 2024. http://hdl.handle.net/11427/41095en_ZA
dc.identifier.citationMotaung, B. 2024. Biomarkers and cell phenotypes in TB patients with minimal or persisting lung inflammation post-anti-TB treatment and ex-vivo atorvastatin immunomodulatory effects on M. tuberculosis-infected PBMC. . University of Cape Town ,Faculty of Health Sciences ,Department of Pathology. http://hdl.handle.net/11427/41095en_ZA
dc.identifier.ris TY - Thesis / Dissertation AU - Motaung, Bongani AB - Unresolved lung inflammation post-anti-TB treatment necessitates the evaluation of additional host-directed therapies (HDT). Statins, recognized for their pleiotropic effects, show potential as immunomodulators to reduce post-TB lung inflammation. The ongoing StatinTB clinical trial utilizes a double-blind, randomized, placebo-controlled approach post-anti-TB treatment to assess the safety and efficacy of atorvastatin in reducing post TB lung inflammation. At the end of TB treatment, Mtb culture-negative participants were stratified into minimal (Arm A, Total Lung Glycolysis (TLG) < 50 SUV) or persisting (Arm B/C, TLG ≥ 50 SUV) lung inflammation using Positron Emission Tomography/Computed Tomography (PET/CT) scan. Arm B/C received atorvastatin (40mg/day) or placebo for 12 weeks, and this data remains currently blinded. Study participants were evaluated for hematological, biochemical, and inflammatory parameters where ALP, proBNP, vitamin D, and CRP showed significant increases in Arm B/C compared to Arm A at DA - 2024 DB - OpenUCT DP - University of Cape Town KW - TB lung inflammation KW - TB treatment KW - tuberculosis LK - https://open.uct.ac.za PB - University of Cape Town PY - 2024 T1 - Biomarkers and cell phenotypes in TB patients with minimal or persisting lung inflammation post-anti-TB treatment and ex-vivo atorvastatin immunomodulatory effects on M. tuberculosis-infected PBMC TI - Biomarkers and cell phenotypes in TB patients with minimal or persisting lung inflammation post-anti-TB treatment and ex-vivo atorvastatin immunomodulatory effects on M. tuberculosis-infected PBMC UR - http://hdl.handle.net/11427/41095 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/41095
dc.identifier.vancouvercitationMotaung B. Biomarkers and cell phenotypes in TB patients with minimal or persisting lung inflammation post-anti-TB treatment and ex-vivo atorvastatin immunomodulatory effects on M. tuberculosis-infected PBMC. []. University of Cape Town ,Faculty of Health Sciences ,Department of Pathology, 2024 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/41095en_ZA
dc.language.isoen
dc.language.rfc3066eng
dc.publisher.departmentDepartment of Pathology
dc.publisher.facultyFaculty of Health Sciences
dc.publisher.institutionUniversity of Cape Town
dc.subjectTB lung inflammation
dc.subjectTB treatment
dc.subjecttuberculosis
dc.titleBiomarkers and cell phenotypes in TB patients with minimal or persisting lung inflammation post-anti-TB treatment and ex-vivo atorvastatin immunomodulatory effects on M. tuberculosis-infected PBMC
dc.typeThesis / Dissertation
dc.type.qualificationlevelDoctoral
dc.type.qualificationlevelPhD
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
thesis_hsf_2024_motaung bongani.pdf
Size:
8.97 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.72 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
PhD / Doctoral